TECTONIC THERAPEUTIC, INC. STOCK TRANSFER AGREEMENTStock Transfer Agreement • September 26th, 2024 • Springer Timothy A • Biological products, (no disgnostic substances) • Delaware
THIS STOCK TRANSFER AGREEMENT (this “Agreement”) is made and entered into on September 24, 2024, (the “Effective Date”) by and between TAS Partners, LLC (the “Transferor”) and the transferees listed on Exhibit A attached hereto (each a “Transferee” and, together, the “Transferees”).
PURCHASE AGREEMENTPurchase Agreement • October 18th, 2023 • Springer Timothy A • Pharmaceutical preparations • Delaware
This PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of May 21, 2021 (the “Trade Date”) by and among each of the entities listed in Exhibit A attached hereto (each a “Seller” and collectively, the “Sellers”), and TAS Partners LLC, a Delaware limited liability company (the “Purchaser”).
JOINT FILING AGREEMENTJoint Filing Agreement • September 26th, 2024 • Springer Timothy A • Biological products, (no disgnostic substances)
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree, as of September 26, 2024, that only one statement containing the information required by Schedule 13D, and each amendment thereto, need be filed with respect to the ownership by each of the undersigned of shares of common stock, par value $0.0001 per share, of Tectonic Therapeutic, Inc., and such statement to which this Joint Filing Agreement is attached as Exhibit 99.4 is filed on behalf of each of the undersigned.
PURCHASE AGREEMENTPurchase Agreement • May 27th, 2021 • Springer Timothy A • Pharmaceutical preparations • Delaware
This PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of May 21, 2021 (the “Trade Date”) by and among each of the entities listed in Exhibit A attached hereto (each a “Seller” and collectively, the “Sellers”), and TAS Partners LLC, a Delaware limited liability company (the “Purchaser”).
JOINT FILING AGREEMENTJoint Filing Agreement • February 14th, 2019 • Springer Timothy A • Biological products, (no disgnostic substances)
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree, as of February 13, 2019, that only one statement containing the information required by Schedule 13G, and each amendment thereto, need be filed with respect to the ownership by each of the undersigned of shares of common stock, $0.001 par value per share of Scholar Rock Holding Corporation, and such statement to which this Joint Filing Agreement is attached as Exhibit 1 is filed on behalf of each of the undersigned.
JOINT FILING AGREEMENTJoint Filing Agreement • June 26th, 2024 • Springer Timothy A • Biological products, (no disgnostic substances)
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree, as of June 26, 2024, that only one statement containing the information required by Schedule 13D, and each amendment thereto, need be filed with respect to the ownership by each of the undersigned of shares of common stock, par value $0.0001 per share, of Tectonic Therapeutic, Inc., and such statement to which this Joint Filing Agreement is attached as Exhibit 99.3 is filed on behalf of each of the undersigned.
JOINT FILING AGREEMENTJoint Filing Agreement • February 14th, 2019 • Springer Timothy A • Biological products, (no disgnostic substances)
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree, as of February 12, 2019, that only one statement containing the information required by Schedule 13G, and each amendment thereto, need be filed with respect to the ownership by each of the undersigned of shares of common stock, $0.0001 par value per share of Moderna, Inc., and such statement to which this Joint Filing Agreement is attached as Exhibit 1 is filed on behalf of each of the undersigned.
JOINT FILING AGREEMENTJoint Filing Agreement • October 18th, 2023 • Springer Timothy A • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree, as of October 18, 2023, that only one statement containing the information required by Schedule 13D, and each amendment thereto, need be filed with respect to the ownership by each of the undersigned of shares of common stock, $0.0001 par value per share of Morphic Holding, Inc., and such statement to which this Joint Filing Agreement is attached as Exhibit 99.4 is filed on behalf of each of the undersigned.
JOINT FILING AGREEMENTJoint Filing Agreement • March 27th, 2019 • Springer Timothy A • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree, as of March 27, 2019, that only one statement containing the information required by Schedule 13D, and each amendment thereto, need be filed with respect to the ownership by each of the undersigned of shares of common stock, $0.0001 par value per share of Selecta Biosciences, Inc., and such statement to which this Joint Filing Agreement is attached as Exhibit 99.3 is filed on behalf of each of the undersigned.
